End-of-day quote
Shenzhen S.E.
18:00:00 2024-04-25 EDT
|
5-day change
|
1st Jan Change
|
3.69
CNY
|
-1.07%
|
|
0.00%
|
-12.97%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
13,759
|
23,523
|
17,064
|
12,738
|
11,085
|
-
|
Enterprise Value (EV)
1 |
13,759
|
23,523
|
17,064
|
12,738
|
11,085
|
11,085
|
P/E ratio
|
24.1
x
|
34
x
|
27
x
|
23.6
x
|
15.4
x
|
13.2
x
|
Yield
|
-
|
-
|
0.53%
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
2.57
x
|
2.08
x
|
1.49
x
|
1.3
x
|
EV / Revenue
|
-
|
-
|
2.57
x
|
2.08
x
|
1.49
x
|
1.3
x
|
EV / EBITDA
|
-
|
-
|
-
|
15.8
x
|
9.85
x
|
8.42
x
|
EV / FCF
|
-
|
-
|
-690,785,883
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
2.06
x
|
1.46
x
|
1.19
x
|
1.1
x
|
Nbr of stocks (in thousands)
|
3,004,155
|
3,004,155
|
3,004,155
|
3,004,155
|
3,004,155
|
-
|
Reference price
2 |
4.580
|
7.830
|
5.680
|
4.240
|
3.690
|
3.690
|
Announcement Date
|
21-02-25
|
22-02-28
|
23-02-27
|
24-02-29
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
6,650
|
6,127
|
7,449
|
8,512
|
EBITDA
1 |
-
|
-
|
-
|
808.5
|
1,125
|
1,316
|
EBIT
1 |
-
|
-
|
712.5
|
511.5
|
813
|
1,000
|
Operating Margin
|
-
|
-
|
10.71%
|
8.35%
|
10.91%
|
11.75%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
716.4
|
629
|
838
|
1,015
|
Net income
1 |
575.6
|
688.3
|
624.2
|
529.2
|
706
|
853
|
Net margin
|
-
|
-
|
9.39%
|
8.64%
|
9.48%
|
10.02%
|
EPS
2 |
0.1900
|
0.2300
|
0.2100
|
0.1800
|
0.2400
|
0.2800
|
Free Cash Flow
|
-
|
-
|
-24.7
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-0.37%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
0.0300
|
-
|
-
|
-
|
Announcement Date
|
21-02-25
|
22-02-28
|
23-02-27
|
24-02-29
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-24.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
7.78%
|
5.97%
|
7.6%
|
8.5%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
4.31%
|
5.2%
|
5.8%
|
-
|
Assets
1 |
-
|
-
|
-
|
12,266
|
13,577
|
14,707
|
-
|
Book Value Per Share
2 |
-
|
-
|
2.760
|
2.900
|
3.110
|
3.360
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
770
|
345
|
420
|
400
|
390
|
Capex / Sales
|
-
|
-
|
11.58%
|
5.63%
|
5.64%
|
4.7%
|
-
|
Announcement Date
|
21-02-25
|
22-02-28
|
23-02-27
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
3.69
CNY Average target price
4
CNY Spread / Average Target +8.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.97% | 1.53B | | +35.04% | 5.92B | | -15.13% | 4.51B | | -9.75% | 3.15B | | +2.14% | 3.1B | | -6.82% | 2.42B | | +47.87% | 1.97B | | -7.89% | 1.68B | | +0.09% | 1.65B | | +33.40% | 1.38B |
Alternative Medicine
|